Targovax have two collaboration trials ongoing:
One is a collaboration with US-based Cancer Research Institute (CRI) and Ludwig Cancer Research (Ludwig, trial sponsor) and AstraZeneca in peritoneal malignancies, and is conducted at five sites in the US.
This is a non-randomized, open-label, multi-center phase I/II trial, with up to 78 patients who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian or colorectal cancer, metastasized to the lining of the abdominal cavity (peritoneum). It is intraperitoneally administered ONCOS-102 in combination with Imfinzi (durvalumab, anti-PD-L1 antibody).
The end-points for the trial are safety, biologic and anti-tumor activity of the combination.
In July 2019 all safety reviews during the dose escalation phase had been completed with no Dose Limiting Toxicities and the expansion part has started.
The other trial is a collaboration with the Czech biotech company Sotio (trial sponsor) in patients with prostate cancer and is conducted at one site in the Czech Republic.
This open label, single-arm phase I/Il trial and will include up to 15 patients with advanced metastatic castration-resistant prostate cancer, testing intra-tumoral ONCOS-102 in combination with Sotio’s dendritic cell therapy DCVAC/PCa.
The end-points for the trial are safety and tolerability of the combination.